- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Teplizumab, Placebo
- Biological · Drug
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 8 Years to 35 Years
- Enrollment
- 554 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 36 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diabetes type1
- Interventions
- AG019 - Low Dose, Teplizumab, Placebo-AG019, Placebo-Teplizumab, AG019 - High Dose
- Biological · Drug
- Lead sponsor
- Precigen Actobio T1D, LLC
- Industry
- Eligibility
- 12 Years to 40 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • San Francisco, California • Ventura, California + 12 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Teplizumab, Placebo
- Biological · Other
- Lead sponsor
- Provention Bio, a Sanofi Company
- Industry
- Eligibility
- 9 Years to 19 Years
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 25
- States / cities
- San Diego, California • San Francisco, California • Walnut Creek, California + 22 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Teplizumab Herold Regimen, Placebo, Teplizumab 33.3% Herold Regimen, Teplizumab Curtailed Herold Regimen
- Biological · Drug
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 8 Years to 35 Years
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 37 more
- Conditions
- Arthritis, Psoriatic
- Interventions
- hOKT3gamma1(Ala-Ala), Placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Chicago, Illinois
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Teplizumab, Placebo
- Drug · Other
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 1 Year to 25 Years
- Enrollment
- 723 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 33
- States / cities
- Scottsdale, Arizona • San Francisco, California • Aurora, Colorado + 28 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- mAb hOKT3gamma1(Ala-Ala), Teplizumab, Placebo Arm
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 8 Years to 30 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 4
- States / cities
- San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 1 more
- Conditions
- Type 1 Diabetes
- Interventions
- Semaglutide (Rybelsus®), Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 12 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- teplizumab, Placebo
- Biological
- Lead sponsor
- Provention Bio, Inc.
- Industry
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 34
- States / cities
- San Diego, California • San Francisco, California • Walnut Creek, California + 30 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Blood samples for safety, Patient reported outcome questionnaires, Analysis of T-cell subsets
- Diagnostic Test · Behavioral
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 10 Years to 37 Years
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes, High Risk, Impaired Glucose Tolerance
- Interventions
- Teplizumab, Placebo infusion
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 8 Years to 45 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 17
- States / cities
- San Francisco, California • Stanford, California • Denver, Colorado + 13 more